Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic

G. Rayman; A. Lumb; B. Kennon; C. Cottrell; D. Nagi; E. Page; D. Voigt; H. Courtney; H. Atkins; J. Platts; K. Higgins; K. Dhatariya; M. Patel; P. Narendran; P. Kar; P. Newland-Jones; R. Stewart; O. Burr; S. Thomas

doi:10.1111/dme.14328

Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic

G. Rayman (Lead / Corresponding author), A. Lumb, B. Kennon, C. Cottrell, D. Nagi, E. Page, D. Voigt, H. Courtney, H. Atkins, J. Platts, K. Higgins, K. Dhatariya, M. Patel, P. Narendran, P. Kar, P. Newland-Jones, R. Stewart, O. Burr, S. Thomas

Postgraduate Medicine

Research output: Contribution to journal › Letter › peer-review

39 Citations (Scopus)

236 Downloads (Pure)

Abstract

During the early stages of the COVID‐19 pandemic, hospitals in London, the UK epicentre, reported an unusually high number of people presenting with COVID‐19 disease developing diabetic ketoacidosis, hyperosmolar hyperglycaemic state, or a combination of both. Very high doses of insulin were often needed to manage the hyperglycaemia. It has been proposed that these metabolic disturbances may result from severe insulin resistance combined with decreased insulin secretion due to beta cell dysfunction.

Original language	English
Pages (from-to)	1214-1216
Number of pages	3
Journal	Diabetic Medicine
Volume	37
Issue number	7
Early online date	18 May 2020
DOIs	https://doi.org/10.1111/dme.14328
Publication status	Published - 18 Jun 2020

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/dme.14328

Author Accepted ManuscriptAccepted author manuscript, 609 KB

Cite this

Rayman, G., Lumb, A., Kennon, B., Cottrell, C., Nagi, D., Page, E., Voigt, D., Courtney, H., Atkins, H., Platts, J., Higgins, K., Dhatariya, K., Patel, M., Narendran, P., Kar, P., Newland-Jones, P., Stewart, R., Burr, O., & Thomas, S. (2020). Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic. Diabetic Medicine, 37(7), 1214-1216. https://doi.org/10.1111/dme.14328

@article{b3729420742944ce8211977244a5e9e4,

title = "Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic",

abstract = "During the early stages of the COVID‐19 pandemic, hospitals in London, the UK epicentre, reported an unusually high number of people presenting with COVID‐19 disease developing diabetic ketoacidosis, hyperosmolar hyperglycaemic state, or a combination of both. Very high doses of insulin were often needed to manage the hyperglycaemia. It has been proposed that these metabolic disturbances may result from severe insulin resistance combined with decreased insulin secretion due to beta cell dysfunction.",

author = "G. Rayman and A. Lumb and B. Kennon and C. Cottrell and D. Nagi and E. Page and D. Voigt and H. Courtney and H. Atkins and J. Platts and K. Higgins and K. Dhatariya and M. Patel and P. Narendran and P. Kar and P. Newland-Jones and R. Stewart and O. Burr and S. Thomas",

year = "2020",

month = jun,

day = "18",

doi = "10.1111/dme.14328",

language = "English",

volume = "37",

pages = "1214--1216",

journal = "Diabetic Medicine",

issn = "0742-3071",

publisher = "Wiley-Blackwell",

number = "7",

}

Rayman, G, Lumb, A, Kennon, B, Cottrell, C, Nagi, D, Page, E, Voigt, D, Courtney, H, Atkins, H, Platts, J, Higgins, K, Dhatariya, K, Patel, M, Narendran, P, Kar, P, Newland-Jones, P, Stewart, R, Burr, O & Thomas, S 2020, 'Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic', Diabetic Medicine, vol. 37, no. 7, pp. 1214-1216. https://doi.org/10.1111/dme.14328

TY - JOUR

T1 - Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic

AU - Rayman, G.

AU - Lumb, A.

AU - Kennon, B.

AU - Cottrell, C.

AU - Nagi, D.

AU - Page, E.

AU - Voigt, D.

AU - Courtney, H.

AU - Atkins, H.

AU - Platts, J.

AU - Higgins, K.

AU - Dhatariya, K.

AU - Patel, M.

AU - Narendran, P.

AU - Kar, P.

AU - Newland-Jones, P.

AU - Stewart, R.

AU - Burr, O.

AU - Thomas, S.

PY - 2020/6/18

Y1 - 2020/6/18

N2 - During the early stages of the COVID‐19 pandemic, hospitals in London, the UK epicentre, reported an unusually high number of people presenting with COVID‐19 disease developing diabetic ketoacidosis, hyperosmolar hyperglycaemic state, or a combination of both. Very high doses of insulin were often needed to manage the hyperglycaemia. It has been proposed that these metabolic disturbances may result from severe insulin resistance combined with decreased insulin secretion due to beta cell dysfunction.

AB - During the early stages of the COVID‐19 pandemic, hospitals in London, the UK epicentre, reported an unusually high number of people presenting with COVID‐19 disease developing diabetic ketoacidosis, hyperosmolar hyperglycaemic state, or a combination of both. Very high doses of insulin were often needed to manage the hyperglycaemia. It has been proposed that these metabolic disturbances may result from severe insulin resistance combined with decreased insulin secretion due to beta cell dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=85085706524&partnerID=8YFLogxK

U2 - 10.1111/dme.14328

DO - 10.1111/dme.14328

M3 - Letter

C2 - 32421882

SN - 0742-3071

VL - 37

SP - 1214

EP - 1216

JO - Diabetic Medicine

JF - Diabetic Medicine

IS - 7

ER -

Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this